Dynamic Regulation of Steroid Hormone Receptor Transcriptional Activity by Reversible SUMOylation

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 227-261

  Knutson, Todd P ^a,b   Lange, Carol A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Androgen receptor; Cancer; Estrogen receptor; Gene expression; Glucocorticoid receptor; Kinases; Microarray; Phosphorylation; Progesterone receptor; SUMOylation; Transcription

Indexed keywords

EID: 84880285016     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00008-3     Document Type: Chapter

References (113)

1. Abdel-Hafiz H.A., Dudevoir M.L., Horwitz K.B. Mechanisms underlying the control of progesterone receptor transcriptional activity by sumoylation. Journal of Biological Chemistry 2009, 284:9099-9108.
2. Abdel-Hafiz H.A., Horwitz K.B. Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Molecular Biology 2012, 13:10.
3. Abdel-Hafiz H., Takimoto G.S., Tung L., Horwitz K.B. The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. Journal of Biological Chemistry 2002, 277:33950-33956.
4. Baker L.A., Allis C.D., Wang G.G. PHD fingers in human diseases: Disorders arising from misinterpreting epigenetic marks. Mutation Research 2008, 647:3-12.
5. Bawa-Khalfe T., Cheng J., Lin S.H., Ittmann M.M., Yeh E.T. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. Journal of Biological Chemistry 2010, 285:25859-25866.
6. Bawa-Khalfe T., Cheng J., Wang Z., Yeh E.T. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. Journal of Biological Chemistry 2007, 282:37341-37349.
7. Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M., Bille K., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98.
8. Bjornstrom L., Sjoberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology 2005, 19:833-842.
9. Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., et al. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Molecular and Cellular Biology 2005, 25:6964-6979.
10. Callewaert L., Verrijdt G., Haelens A., Claessens F. Differential effect of small ubiquitin-like modifier (SUMO)-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. Molecular Endocrinology 2004, 18:1438-1449.
11. Carroll J., Meyer C., Song J., Li W., Geistlinger T., Eeckhoute J., et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 2006, 38:1289-1297.
12. Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. Journal of Biological Chemistry 2003, 278:12335-12343.
13. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell & Melanoma Research 2010, 23:27-40.
14. Cheng J., Bawa T., Lee P., Gong L., Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 2006, 8:667-676.
15. Cheng J., Wang D., Wang Z., Yeh E.T. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Molecular and Cellular Biology 2004, 24:6021-6028.
16. Chupreta S., Holmstrom S., Subramanian L., Iniguez-Lluhi J.A. A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties. Molecular and Cellular Biology 2005, 25:4272-4282.
17. Daniel A.R., Faivre E.J., Lange C.A. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Molecular Endocrinology 2007, 21:2890-2906.
18. Daniel A.R., Lange C.A. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14287-14292.
19. Danielian P.S., White R., Lees J.A., Parker M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. The EMBO Journal 1992, 11:1025-1033.
20. Dünnebier T., Bermejo J., Haas S., Fischer H., Pierl C., Justenhoven C., et al. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk. Breast Cancer Research and Treatment 2010, 121:185-194.
21. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annual Review of Physiology 2005, 67:335-376.
22. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. Journal of Biological Chemistry 2000, 275:20853-20860.
23. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Research 2000, 60:4026-4029.
24. Gareau J.R., Lima C.D. The SUMO pathway: Emerging mechanisms that shape specificity, conjugation and recognition. Nature Reviews. Molecular Cell Biology 2010, 11:861-871.
25. Gaughan L., Logan I.R., Cook S., Neal D.E., Robson C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Journal of Biological Chemistry 2002, 277:25904-25913.
26. Gilbreth R.N., Truong K., Madu I., Koide A., Wojcik J.B., Li N.S., et al. Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7751-7756.
27. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Current Opinion in Genetics & Development 2003, 13:108-113.
28. Giordano C., Cui Y., Barone I., Ando S., Mancini M.A., Berno V., et al. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Research and Treatment 2010, 119:71-85.
29. Gong L., Millas S., Maul G.G., Yeh E.T. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. Journal of Biological Chemistry 2000, 275:3355-3359.
30. Gottlicher M., Heck S., Doucas V., Wade E., Kullmann M., Cato A.C., et al. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. Steroids 1996, 61:257-262.
31. Grontved L., Hager G.L. Impact of chromatin structure on PR signaling: Transition from local to global analysis. Molecular and Cellular Endocrinology 2012, 357:30-36.
32. Gross M., Yang R., Top I., Gasper C., Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 2004, 23:3059-3066.
33. Guo D., Li M., Zhang Y., Yang P., Eckenrode S., Hopkins D., et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nature Genetics 2004, 36:837-841.
34. Han B.Y., Li F.C., Cheng L., Xu X.J., Jiang K., Fu J., et al. SUMO-2/3 can covalently bind to progesterone receptor B to regulate its transcriptional activity]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2011, 31:1493-1497.
35. Hay R.T. SUMO: A history of modification. Molecular Cell 2005, 18:1-12.
36. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387:733-736.
37. Herynk M.H., Hopp T., Cui Y., Niu A., Corona-Rodriguez A., Fuqua S.A. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Research and Treatment 2010, 122:381-393.
38. Herynk M.H., Parra I., Cui Y., Beyer A., Wu M.F., Hilsenbeck S.G., et al. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13:3235-3243.
39. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., et al. PDSM, a motif for phosphorylation-dependent SUMO modification. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:45-50.
40. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985, 318:635-641.
41. Holmstrom S., Chupreta S., So A., Iñiguez-Lluhí J. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on Daxx. Molecular Endocrinology 2008, 22:2061-2075.
42. Holmstrom S., Van Antwerp M.E., Iniguez-Lluhi J.A. Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15758-15763.
43. Huang W.C., Ko T.P., Li S.S., Wang A.H. Crystal structures of the human SUMO-2 protein at 1.6 A and 1.2 A resolution: Implication on the functional differences of SUMO proteins. European Journal of Biochemistry/FEBS 2004, 271:4114-4122.
44. Iniguez-Lluhi J.A., Pearce D. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Molecular and Cellular Biology 2000, 20:6040-6050.
45. Johnson E.S. Protein modification by SUMO. Annual Review of Biochemistry 2004, 73:355-382.
46. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
47. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
48. Kaul S., Blackford J.A., Cho S., Simons S.S. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. Journal of Biological Chemistry 2002, 277:12541-12549.
49. Kim E.J., Park J.S., Um S.J. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML. Nucleic Acids Research 2003, 31:5356-5367.
50. Knutson T.P., Daniel A.R., Fan D., Silverstein K.A., Covington K.R., Fuqua S.A., et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Research 2012, 14:R95.
51. Kobayashi S., Shibata H., Yokota K., Suda N., Murai A., Kurihara I., et al. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocrine Research 2004, 30:617-621.
52. Kotaja N., Karvonen U., Janne O.A., Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Molecular and Cellular Biology 2002, 22:5222-5234.
53. Kotaja N., Vihinen M., Palvimo J.J., Janne O.A. Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. Journal of Biological Chemistry 2002, 277:17781-17788.
54. Lange C.A. Integration of progesterone receptor action with rapid signaling events in breast cancer models. The Journal of Steroid Biochemistry and Molecular Biology 2008, 108:203-212.
55. Lange C.A., Shen T., Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:1032-1037.
56. Le Drean Y., Mincheneau N., Le Goff P., Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002, 143:3482-3489.
57. Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S., Bouchekioua-Bouzaghou K., et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Molecular Cell 2008, 31:212-221.
58. Lee F.Y., Faivre E.J., Suzawa M., Lontok E., Ebert D., Cai F., et al. Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development. Developmental Cell 2011, 21:315-327.
59. Li X., Lee Y.K., Jeng J.C., Yen Y., Schultz D.C., Shih H.M., et al. Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. Journal of Biological Chemistry 2007, 282:36177-36189.
60. Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.J., et al. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Molecular and Cellular Biology 2000, 20:1784-1796.
61. Li R., Pei H., Watson D.K., Papas T.S. EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene 2000, 19:745-753.
62. Lieberman B.A., Bona B.J., Edwards D.P., Nordeen S.K. The constitution of a progesterone response element. Molecular Endocrinology 1993, 7:515-527.
63. Lin D.Y., Fang H.I., Ma A.H., Huang Y.S., Pu Y.S., Jenster G., et al. Negative modulation of androgen receptor transcriptional activity by Daxx. Molecular and Cellular Biology 2004, 24:10529-10541.
64. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Molecular Cell 2006, 24:341-354.
65. Lin D.Y., Lai M.Z., Ann D.K., Shih H.M. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. Journal of Biological Chemistry 2003, 278:15958-15965.
66. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 2008, 68:6407-6415.
67. Lonard D.M., Nawaz Z., Smith C.L., O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Molecular Cell 2000, 5:939-948.
68. Losel R., Wehling M. Nongenomic actions of steroid hormones. Nature Reviews. Molecular Cell Biology 2003, 4:46-56.
69. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
70. Mahajan R., Delphin C., Guan T., Gerace L., Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88:97-107.
71. Man J.-H., Li H.-Y., Zhang P.-J., Zhou T., He K., Pan X., et al. PIAS3 induction of PRB sumoylation represses PRB transactivation by destabilizing its retention in the nucleus. Nucleic Acids Research 2006, 34:5552-5566.
72. Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009, 324:407-410.
73. Misrahi M., Atger M., d'Auriol L., Loosfelt H., Meriel C., Fridlansky F., et al. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochemical and Biophysical Research Communications 1987, 143:740-748.
74. Mohideen F., Capili A.D., Bilimoria P.M., Yamada T., Bonni A., Lima C.D. A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nature Structural & Molecular Biology 2009, 16:945-952.
75. Mukherjee S., Thomas M., Dadgar N., Lieberman A.P., Iniguez-Lluhi J.A. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. Journal of Biological Chemistry 2009, 284:21296-21306.
76. Nishida T., Kaneko F., Kitagawa M., Yasuda H. Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. Journal of Biological Chemistry 2001, 276:39060-39066.
77. Nishida T., Yasuda H. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. Journal of Biological Chemistry 2002, 277:41311-41317.
78. O'Malley B.W., Kumar R. Nuclear receptor coregulators in cancer biology. Cancer Research 2009, 69:8217-8222.
79. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
80. Owerbach D., McKay E.M., Yeh E.T., Gabbay K.H., Bohren K.M. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochemical and Biophysical Research Communications 2005, 337:517-520.
81. Picard N., Caron V., Bilodeau S., Sanchez M., Mascle X., Aubry M., et al. Identification of estrogen receptor beta as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3beta. Molecular and Cellular Biology 2012, 32:2709-2721.
82. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Janne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. Journal of Biological Chemistry 1999, 274:19441-19446.
83. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proceedings of the National Academy of Sciences of the United States of America 2000, 97:14145-14150.
84. Robinson-Rechavi M., Carpentier A.S., Duffraisse M., Laudet V. How many nuclear hormone receptors are there in the human genome?. Trends in genetics: TIG 2001, 17:554-556.
85. Ruthenburg A.J., Allis C.D., Wysocka J. Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark. Molecular Cell 2007, 25:15-30.
86. Ryu S.W., Chae S.K., Kim E. Interaction of Daxx, a Fas binding protein, with sentrin and Ubc9. Biochemical and Biophysical Research Communications 2000, 279:6-10.
87. Saitoh H., Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. Journal of Biological Chemistry 2000, 275:6252-6258.
88. Sentis S., Le Romancer M., Bianchin C., Rostan M.-C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular Endocrinology 2005, 19:2671-2684.
89. Shalizi A., Gaudilliere B., Yuan Z., Stegmuller J., Shirogane T., Ge Q., et al. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006, 311:1012-1017.
90. Shao R., Zhang F.-P., Rung E., Palvimo J.J., Huhtaniemi I., Billig H. Inhibition of small ubiquitin-related modifier-1 expression by luteinizing hormone receptor stimulation is linked to induction of progesterone receptor during ovulation in mouse granulosa cells. Endocrinology 2004, 145:384-392.
91. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95:927-937.
92. So A.Y., Chaivorapol C., Bolton E.C., Li H., Yamamoto K.R. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genetics 2007, 3:e94.
93. Song J., Durrin L.K., Wilkinson T.A., Krontiris T.G., Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:14373-14378.
94. Strauss J.F., Schuler L.A., Rosenblum M.F., Tanaka T. Cholesterol metabolism by ovarian tissue. Advances in Lipid Research 1981, 18:99-157.
95. Su B., Wong C., Hong Y., Chen S. Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms. The Journal of Steroid Biochemistry and Molecular Biology 2011, 123:101-108.
96. Suzuki T., Miki Y., Nakamura Y., Moriya T., Ito K., Ohuchi N., et al. Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 2005, 12:701-720.
97. Takimoto G.S., Tung L., Abdel-Hafiz H., Abel M.G., Sartorius C.A., Richer J.K., et al. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. The Journal of Steroid Biochemistry and Molecular Biology 2003, 85:209-219.
98. Tang Q., Chen Y., Meyer C., Geistlinger T., Lupien M., Wang Q., et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Research 2011, 71:6940-6947.
99. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M., Botting C.H., Naismith J.H., et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. Journal of Biological Chemistry 2001, 276:35368-35374.
100. Taverna S.D., Li H., Ruthenburg A.J., Allis C.D., Patel D.J. How chromatin-binding modules interpret histone modifications: Lessons from professional pocket pickers. Nature Structural & Molecular Biology 2007, 14:1025-1040.
101. Tetel M.J., Giangrande P.H., Leonhardt S.A., McDonnell D.P., Edwards D.P. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Molecular Endocrinology 1999, 13:910-924.
102. Thomas M., Dadgar N., Aphale A., Harrell J.M., Kunkel R., Pratt W.B., et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. Journal of Biological Chemistry 2004, 279:8389-8395.
103. Tian S., Poukka H., Palvimo J.J., Janne O.A. Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochemical Journal 2002, 367:907-911.
104. Tirard M., Almeida O.F., Hutzler P., Melchior F., Michaelidis T.M. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor. Molecular and Cellular Endocrinology 2007, 268:20-29.
105. Verzi M.P., Shin H., He H.H., Sulahian R., Meyer C.A., Montgomery R.K., et al. Differentiation-specific histone modifications reveal dynamic chromatin interactions and partners for the intestinal transcription factor CDX2. Developmental Cell 2010, 19:713-726.
106. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. Journal of Biological Chemistry 2001, 276:18375-18383.
107. Wang Q., Xia N., Li T., Xu Y., Zou Y., Zuo Y., et al. SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene 2013, 32(19):2493-2498. 10.1038/onc.2012.250.
108. Wu H., Sun L., Zhang Y., Chen Y., Shi B., Li R., et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. Journal of Biological Chemistry 2006, 281:21848-21856.
109. Xu J., Wu R.-C., O'malley B.W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Reviews. Cancer 2009, 9:615-630.
110. Yang S.H., Galanis A., Witty J., Sharrocks A.D. An extended consensus motif enhances the specificity of substrate modification by SUMO. The EMBO Journal 2006, 25:5083-5093.
111. Yang S.H., Jaffray E., Senthinathan B., Hay R.T., Sharrocks A.D. SUMO and transcriptional repression: Dynamic interactions between the MAP kinase and SUMO pathways. Cell Cycle 2003, 2:528-530.
112. Yang Y., Tse A.K., Li P., Ma Q., Xiang S., Nicosia S.V., et al. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 2011, 30:2207-2218.
113. Zhang P.J., Zhao J., Li H.Y., Man J.H., He K., Zhou T., et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. The EMBO Journal 2007, 26:1831-1842.